Orchestra BioMed (OBIO) Corporate presentation summary

Strategic vision and business model

• Focused on leveraging partnerships to accelerate innovation and drive future profitability in cardiovascular medicine.

• Employs a royalty-based revenue model through strategic collaborations with industry leaders.

• Fully funded through pivotal trial enrollment and AVIM Therapy primary endpoint data readout.

Flagship programs and clinical pipeline

• Two pivotal trial-stage programs: AVIM Therapy for hypertension and Virtue SAB for artery disease.

• AVIM Therapy targets pacemaker-indicated hypertension and broader high-risk populations, with FDA Breakthrough Device Designation.

• Virtue SAB is a novel, non-coated, sirolimus drug delivery balloon for coronary and peripheral artery disease, also with FDA Breakthrough Device Designation.

• Both programs address large global markets with significant unmet clinical needs.

Recent accomplishments and upcoming catalysts

• Expanded eligibility and ongoing enrollment in the BACKBEAT pivotal study for AVIM Therapy.

• Launched Virtue Trial in coronary in-stent restenosis and secured strategic rights agreement with Terumo.

• Secured cash runway into Q4 2027 through strategic transactions and milestone payments.